Government policy is hurting creativity say Nobel Laureates
This article was originally published in Scrip
Executive Summary
A clutch of Nobel Laureates believe that directing government research funding to projects that are expected to produce economic benefits is misguided. The UK's switch in the 1970s to more targeted research funding, for example, correlated with a decline 20 years later in the number of prizes that the country won. The big advances in science, and resultant economic benefit, come from discoveries that cannot be predicted, claim Sir Tim Hunt, Sir Aaron Klug and others, in a letter to the Financial Times (June 24th, p 14).
You may also be interested in...
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.
Theravance's Gut-Selective JAK Inhibitor Disappoints In Ulcerative Colitis Study
Top-line results from a Phase IIb study of Theravance’s potential gut-selective JAK inhibitor izencitinib have not matched expectations, and results from a similar early-stage study in Crohn’s disease with the Janssen-partnered candidate are now awaited at the end of the year or in early 2022.